ReviewAddiction (Abingdon, England)2016

Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.

Niamh Fitzgerald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.